CoChat

Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2

Open access
Chiotos, Kathleen, Hayes, Molly, Kimberlin, David W, Jones, Sarah B, James, Scott H, Pinninti, Swetha G, Yarbrough, April, Abzug, Mark J, MacBrayne, Christine E, Soma, Vijaya L, Dulek, Daniel E, Vora, Surabhi B, Waghmare, Alpana, Wolf, Joshua, Olivero, Rosemary, Grapentine, Steven, Wattier, Rachel L, Bio, Laura, Cross, Shane J, Dillman, Nicholas O, Downes, Kevin J, Timberlake, Kathryn, Young, Jennifer, Orscheln, Rachel C, Tamma, Pranita D, Schwenk, Hayden T, Zachariah, Philip, Aldrich, Margaret, Goldman, David L, Groves, Helen E, Lamb, Gabriella S, Tribble, Alison C, Hersh, Adam L, Thorell, Emily A, Denison, Mark R, Ratner, Adam J, Newland, Jason G, Nakamura, Mari M · 2020 · Journal of the Pediatric Infectious Diseases Society
Cited by 183

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

Abstract

Background: Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. Methods: A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion. Results: Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available. Conclusions: Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare cases of severe or critical disease, this guidance offers an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jpids/piaa045

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 145 references

Cited by

Metadata

Authors
Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A., Abzug, M. J., MacBrayne, C. E., Soma, V. L., Dulek, D. E., Vora, S. B., Waghmare, A., Wolf, J., Olivero, R., Grapentine, S., Wattier, R. L., Bio, L., Cross, S. J., Dillman, N. O., Downes, K. J., Timberlake, K., Young, J., Orscheln, R. C., Tamma, P. D., Schwenk, H. T., Zachariah, P., Aldrich, M., Goldman, D. L., Groves, H. E., Lamb, G. S., Tribble, A. C., Hersh, A. L., Thorell, E. A., Denison, M. R., Ratner, A. J., Newland, J. G., & Nakamura, M. M.
Venue
Journal of the Pediatric Infectious Diseases Society
Published
2020-04-22
Volume
9
Issue
6
Pages
701-715
ISSN
  • 2048-7193 (ISSN-L)
  • 2048-7207
OpenAlex
W3016479590
Cited by
183
References
145
FWCI
5.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.